Acumen Pharmaceuticals, Inc. (ABOS)
0.2432
+0.02
(+8.81%)
USD |
NASDAQ |
Nov 09, 11:47
Acumen Pharmaceuticals Debt to Equity Ratio : 0.7602 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.7602 |
| June 30, 2026 | 0.5526 |
| March 31, 2026 | 0.3562 |
| December 31, 2025 | 0.4446 |
| September 30, 2025 | 0.331 |
| June 30, 2025 | 0.2571 |
| March 31, 2025 | 0.1915 |
| December 31, 2024 | 0.1634 |
| September 30, 2024 | 0.1381 |
| June 30, 2024 | 0.1218 |
| March 31, 2024 | 0.1167 |
| December 31, 2023 | 0.1163 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.0002 |
| March 31, 2023 | 0.0004 |
| December 31, 2022 | 0.0006 |
| September 30, 2022 | 0.0007 |
| June 30, 2022 | 0.0008 |
| March 31, 2022 | 0.0009 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.241 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 85.56M |
| Total Liabilities (Quarterly) | 50.96M |
| Shareholders Equity (Quarterly) | 34.61M |
| Current Ratio | 1.888 |
| Net Debt Paydown Yield | 0.47% |